$AOYUAN HEALTHY(03662)$With the newly revised annual caps, it means there is an agreement with China Aoyuan to raise the minimum revenue caps for Aoyuan Healthy. It is a promising sign that the actual revenue for FY2021-23 may see a revision upwards. Using FY2020 as a historical example- the FY2020 revised cap was published at 705000000 RMB and the actual came in at 1408089000 RMB, about double. Here are FY2021-23 revised annual caps and you can make a good estimate of what the future revenue would be :
FY2020 - 705000000 RMB
FY2021 - 1036620000 RMB (+47% YOY)
FY2022 - 1381890000 RMB (+33.3%)
FY2023 - 1842900000 RMB (+33.3%)
The revenue growth for FY2021 can be estimated to be 47%. With FY2020 EPS of $0.41, the estimate FY2021 EPS is $0.60. Assuming a Forward FY2021 PE of 15 (conservative, peers at 23-30) the target price is >$9.00. Highly recommended to buy even after it rose 15% today.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- 酷酷wellen·2021-06-09目标是9美元还是9港币？LikeReport
- ValueTrade·2021-06-08Added another 8% today with heavy trading Net money inflow of $24M. Yesterday net money inflow of $19M but closed 15% higher. Expect heavy buying tmrw barring unforseen circumstances.1Report
- meizeng81·2021-08-23do u advise to hold this stock ?LikeReport